Bharat Biotech's COVAXIN neutralises multiple variants of SARS-CoV-2 and double mutant strain: ICMR study

[Mirage]

KEY HIGHLIGHTS

• COVAXIN neutralises multiple variants of SARS-CoV-2

• It effectively neutralises the double mutant strain as well

• Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries

New Delhi: ICMR study shows that COVAXIN made by Bharat Biotech is effective against multiple variants of SARS-CoV-2 and effectively neutralizes the double mutant strain as well.

ICMR NIV has demonstrated the neutralization potential of COVAXIN against the UK variant and Brazil variant.

ICMR has recently been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 which has been identified in certain regions of India and several other countries.

Concerns were raised over the efficacy of Covaxin

Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process.

In January, Chhattisgarh health minister TS Singh Deo said the use of COVAXIN should not be allowed as its trial has not been completed yet.

 “The third phase trial of Covaxin is under process. The vaccine has been approved for emergency use (by the Drug Controller General of India). Its use should be avoided until its complete results are out,” he had said.

Resident doctors at Delhi's Ram Manohar Lohia (RML) Hospital had also expressed concern over the lack of complete trial in the case of Covaxin and said they would prefer Covishield jab. 

Bharat Biotech ramps up production capacity to 700 mn doses per annum

Amid reports of vaccine shortage in India and to boost the vaccination campaigns across the globe, Bharat Biotech has ramped up the manufacturing capacity of COVAXIN, to 700 million doses per annum.

Manufacturing scale-up has been carried out in a stepwise manner across multiple facilities at Hyderabad and Bangalore, the company said in a statement.

Finance Minister Nirmala Sitharaman had recently approved a total of Rs 4,567.50 crore as advance payment to Serum Institute of India (SII) and Bharat Biotech to ramp up vaccine production against coronavirus.

The government has approved Rs 3,000 crores of financial assistance for SII and Rs 1567.50 crores to Bharat Biotech which will be released soon to these companies.

[Mirage]

@ZoomNaidu @jawaani_jaaneman @Sachin200 @karthik25 @NiranjanGaaru @Subbulu @DummyVariable@Sputnik @dewarist @Ryzen_renoir

[jawaani_jaaneman]

That's actually a good study, indulo emana manage chesinaro ledo kani..

Home grown vaccine..mana gene ki tagattu tayar chesuntaru..i may be wrong but desi is desi.

[Mirage]

28 minutes ago, jawaani_jaaneman said:

That's actually a good study, indulo emana manage chesinaro ledo kani..

Home grown vaccine..mana gene ki tagattu tayar chesuntaru..i may be wrong but desi is desi.

There were concerns about the double mutant variant.. so this is a good news.

 

[PizzaReddy]

Thank you Modiji